

DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Immunologicals – Adbry Drug Quantity Management Policy – Per Days

- Adbry™ (tralokinumab-ldrm subcutaneous injection – Leo)

REVIEW DATE: 12/01/2022

OVERVIEW

Adbry, an interleukin (IL)-13 antagonist, is indicated for the treatment of moderate to severe **atopic dermatitis** in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.¹ Adbry may be used with or without topical corticosteroids.

Dosing

The recommended initial dose of Adbry is 600 mg by subcutaneous (SC) injection (four 150 mg injections) once, followed by 300 mg SC (two 150 mg injections) once every 2 weeks.¹ Following 16 weeks of treatment, a dose of 300 mg SC once every 4 weeks may be considered in patients weighing < 100 kg who achieve clear or almost clear skin. Adbry should be used under the guidance of a healthcare provider; however, it may be self-administered following SC injection training.

Availability

Adbry is available as 150 mg/mL prefilled syringes supplied in packs of two or four syringes.¹

POLICY STATEMENT

This Drug Quantity Management program has been developed to manage potential dose escalation of Adbry. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Automation: None.

Drug Quantity Limits

Product	Strength and Form	Retail Maximum Quantity per 28 Days	Home Delivery Maximum Quantity per 84 Days
Adbry™ (tralokinumab-ldrm SC injection)	150 mg/mL prefilled syringes	4 prefilled syringes [†]	12 prefilled syringes [†]

SC – Subcutaneous; [†] This provides a quantity sufficient for dosing at 300 mg given once every 2 weeks.

CRITERIA

1. If the patient is initiating therapy, as verified by the absence of claims for Adbry in the past 130 days, approve a one-time override for up to 6 prefilled syringes for 28-day supply at retail or 14 prefilled syringes for an 84-day supply at home delivery.

Note: The retail quantity of 6 prefilled pens or prefilled syringes provides a quantity sufficient for the initial loading dose of 600 mg (four 150 mg injections) followed by 300 mg (two 150 mg injections) once every 2 weeks thereafter for 28 days. The home delivery quantity of 14 prefilled pens or prefilled syringes provides for the initial loading dose of 600 mg (four 150 mg injections) followed by 300 mg (two 150 mg injections) once every 2 weeks thereafter for a total of 84 days.

REFERENCES

1. Adbry® subcutaneous injection [prescribing information]. Madison, NJ: Leo; December 2021.